Glial Fibrillary Acidic Protein

The GFAP gene encodes glial fibrillary acidic protein, a key structural component of astrocytes—the star-shaped support cells of the central nervous system. 

GFAP plays a central role in maintaining astrocyte integrity, responding to injury, and serving as both a diagnostic biomarker and the genetic basis of Alexander disease when mutated.

What is Glial Fibrillary Acidic Protein (GFAP)?

The GFAP gene encodes glial fibrillary acidic protein (GFAP), a type III intermediate filament protein primarily found in astrocytes, the most abundant glial cells in the central nervous system (CNS). 

GFAP is a major structural protein in the astrocytic cytoskeleton, essential for maintaining these cells' shape, strength, and function. 

Astrocytes play key roles in maintaining CNS homeostasis by supporting neurons, regulating neurotransmitters, maintaining the blood-brain barrier, and responding to injury.

GFAP is normally expressed at low levels but is upregulated during CNS injury or disease. Elevated GFAP expression contributes to astrocyte activation (reactive gliosis) and is often seen in various neurological conditions. 

Clinically, GFAP is widely used as a diagnostic and research marker to identify astrocytes in tissue samples.

GFAP: A Structural Protein in Astrocytes

GFAP belongs to the intermediate filament family, which forms part of the cellular scaffolding that maintains astrocyte shape and structural integrity. 

GFAP polymers create filamentous networks that help astrocytes resist mechanical stress and maintain normal interactions with neurons and other glial cells.

Astrocyte Function

Astrocytes are critical for multiple CNS functions:

• Blood-brain barrier maintenance: Regulate permeability and protect the brain from toxins and pathogens.
• Neuronal support: Stabilize neurons and synapses.
• Neurotransmitter regulation: Assist in the clearance and recycling of neurotransmitters like glutamate.
• Response to injury and inflammation: Activate and increase GFAP production following trauma, ischemia, infection, or neurodegeneration.

GFAP Expression

GFAP is highly specific to astrocytes, making it a valuable biomarker in immunohistochemistry. Several isoforms exist (e.g., GFAP-α, GFAP-ε, GFAP-κ), with GFAP-α being the most abundant. Expression is modulated by injury, stress, and various molecular regulators.

GFAP Mutations: Alexander Disease

GFAP mutations are associated with a rare disease called Alexander disease.

Alexander disease is a rare, inherited disorder classified as a leukodystrophy, which is a group of conditions that damage the white matter (the part of the brain and spinal cord that helps transmit signals between nerve cells) due to problems with the myelin sheath. 

Alexander disease is caused by a gain-of-function mutation in the GFAP gene, which leads to abnormal buildup of a protein called glial fibrillary acidic protein (GFAP) inside astrocytes.

This buildup forms clumps called Rosenthal fibers, which interfere with astrocyte function and contribute to progressive damage of the brain's white matter.

The disease can begin at any age, but it is most severe when it starts in infancy or early childhood, often causing macrocephaly (enlarged head), developmental delays, muscle stiffness (spasticity), seizures, and difficulties with swallowing and speaking (bulbar signs). 

Brain imaging (MRI) typically shows characteristic changes in the white matter, especially in the front of the brain, while genetic testing confirms the diagnosis. 

There is currently no cure; treatment is focused on managing symptoms with medications, physical therapy, nutritional support, and sometimes surgery. New therapies aiming to reduce abnormal GFAP protein levels are under investigation.

When is GFAP Testing Relevant?

GFAP testing may be relevant in the following settings:

Evaluation of CNS Injury or Disease

GFAP can be measured in cerebrospinal fluid (CSF) or blood and is elevated when astrocytes are damaged or activated.

Traumatic Brain Injury (TBI)

GFAP is a sensitive biomarker for acute brain injury, including mild TBI (concussion) and more severe cases. Higher levels often correlate with injury severity and prognosis.

Stroke

GFAP increases after ischemic or hemorrhagic stroke, reflecting astrocyte damage.

Multiple Sclerosis (MS)

GFAP may be elevated during MS relapses or in progressive forms.

Neurodegenerative Diseases

GFAP has emerging value in Alzheimer's disease, frontotemporal dementia, and related disorders.

Neuromyelitis Optica Spectrum Disorder (NMOSD)

GFAP is particularly relevant due to its association with astrocyte-targeted autoimmune pathology.

Astrocytic Tumors

GFAP is routinely used to identify astrocytic origin in CNS tumors.

Differential Diagnosis

GFAP testing may help distinguish between different types of CNS injury, demyelinating diseases, and neurodegenerative disorders. However, elevated GFAP is not disease-specific and should be interpreted in the full clinical context.

GFAP Protein Testing Process and Interpretation

GFAP protein testing uses peripheral blood samples (plasma or serum), offering a minimally invasive alternative to cerebrospinal fluid (CSF) testing. 

The most common method for quantifying GFAP levels is the single-molecule array (Simoa) platform, an advanced and highly sensitive immunoassay capable of detecting low concentrations of GFAP in blood. 

What Do High Levels of GFAP Mean?

Elevated GFAP reflects astrocyte activation or damage and is commonly seen in:

• Acute CNS injuries (e.g., TBI, stroke)
• Inflammatory disorders (e.g., MS, NMOSD)
• Neurodegenerative diseases (e.g., Alzheimer's disease, although high GFAP levels may distinguish the condition from neurodegeneration associated with high beta amyloid levels)
• Astrocytic tumors

High GFAP levels often correlate with disease severity and prognosis. However, GFAP elevation is non-specific and should be evaluated alongside imaging, clinical findings, and other biomarkers (e.g., tau, neurofilament light chain).

What Do Low or Normal Levels of GFAP Mean?

Low or normal levels of the GFAP protein are less likely to indicate acute CNS injury or active astrocytic pathology.

However, this does not exclude disease: In chronic, slowly progressive, or early-stage diseases, GFAP may remain within normal ranges despite underlying pathology.

Mild injuries may not trigger significant GFAP elevation.

GFAP Genetic Testing: Test Procedure and Interpretation

Testing for GFAP is performed as a genetic test to look for mutations in the gene that would alter functional protein availability. The following section outlines the testing procedures and interpretation.

Testing Procedure and Preparation

Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types. 

A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.

Normal Reference Ranges

Normal reference ranges for GFAP genetic testing are considered to be without mutations that can alter the activity of the GFAP proteins.

Clinical Implications of Positive GFAP Mutations

The clinical implications of a positive GFAP mutation test result will vary by individual. However, GFAP mutations in symptomatic patients may signal a need for further assessment and possibly treatment, especially in the setting of neuropathic symptoms.

Patients or practitioners with questions about the clinical implications of GFAP mutations should seek further assessment with a genetic counselor or expert. 

What Does the Absence of Pathogenic GFAP Mutations Mean?

The absence of GFAP mutations does not rule out inherited neuropathies, as the spectrum of leukodystrophies are genetically heterogeneous. Many other genes are known to cause similar clinical presentations. 

A negative GFAP result should prompt consideration of further genetic testing, particularly if there is a strong clinical suspicion of hereditary neuropathy.

Practical Notes for Clinicians

Testing: GFAP is measurable in CSF, blood, or tissue via immunohistochemistry or ultrasensitive assays (e.g., Simoa).

Interpretation: Always consider GFAP levels in the clinical context.

Emerging role: GFAP is being explored as a non-invasive biomarker for monitoring neurodegeneration (e.g., Alzheimer's disease) and guiding prognosis in TBI.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.